Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
31 hedge funds and large institutions have $5.42M invested in Acorda Therapeutics in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 5 closing their positions.
950% more call options, than puts
Call options by funds: $63K | Put options by funds: $6K
3% less funds holding
Funds holding: 32 → 31 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
43% less capital invested
Capital invested by funds: $9.48M → $5.42M (-$4.06M)
78% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$26.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.51K |
| 3 |
Citigroup
New York
|
+$3.26K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.14K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$983 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$674K |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$193K |
| 3 |
Invesco
Atlanta,
Georgia
|
-$186K |
| 4 |
Millennium Management
New York
|
-$98.4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$59.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCM
26
Highbridge Capital Management
New York
| – | -$674K | -14,110 | Closed |
|
|
27
Invesco
Atlanta,
Georgia
| – | -$186K | -3,893 | Closed |
|
|
28
Bank of America
Charlotte,
North Carolina
| – | -$59.8K | -1,520 | Closed |
|
29
William Blair & Company
Chicago,
Illinois
| – | -$57K | -1,192 | Closed |
|
30
Citadel Advisors
Miami,
Florida
| – | -$28.4K | -723 | Closed |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.1K | -28 | -62% |
|
|
CAL
32
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | +$79 | +2 | New |
|
ACOR Hedge Fund Activity: Q1 2022 in Review
31 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2022, worth a combined $5.42M — down 43% from $9.48M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ACOR and 4 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 2 added.
The largest buyer was Jane Street, opening a new position worth an estimated $26.5K. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $674K sold.
- 31 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2022, down from 32 in Q4 2021.
- Funds reported $5.42M of Acorda Therapeutics stock for Q1 2022, down 43% quarter-over-quarter.
- 4 funds opened new Acorda Therapeutics positions in Q1 2022 and 5 closed out, a net change of -1 holder.
- The largest Acorda Therapeutics buyer in Q1 2022 was Jane Street, an estimated $26.5K added.
- The largest Acorda Therapeutics seller in Q1 2022 was Highbridge Capital Management, an estimated $674K sold.
Based on aggregated 13F filings for Q1 2022.